



Email: smpu@scimedpress.com

SMP Urology and Research

Clear cell carcinoma of the urinary bladder, case report and literature review

Z. Hashemi^{1*}, KJ Lentjes¹, D Houtsma², R Natté³ and H Roshani¹

¹Department of urology, Haga teaching hospital, The Hague, The Netherlands ²Department of oncology, Haga teaching hospital, The Hague, The Netherlands ³Department of pathology, Haga teaching hospital, The Hague, The Netherlands

Publication Dates

Received date: February 03, 2023 Accepted date: March 03, 2023 Published date: March 10, 2023

Corresponding Author

* Z Hashemi, Department of urology, Haga teach-ing hos-pital, The Hague, The Neth-erlands, Tel: +31 0648783278, E-mail: zahra_mitra@hotmail.nl

Citation

Z Hashemi, KJ Lentjes, D Houtsma, R Natté and H Roshani (2023), Clear cell carcinoma of the urinary bladder, case report and literature review. SMP Urol Res. 1: 1-10. Abstract

Primary clear cell carcinoma (CCC) is a rare type of malignancy occasionally found in the urinary bladder. While CCC is common and histologically similar to the neoplasm in the female genital tract; the histogenesis and biological behavior of this neoplasm, specifically in the bladder, has not yet been thoroughly investigated or understood. Standard treatment options have also not been established, due to lack and sparsity of available research. We present a case of clear cell carcinoma of the urinary bladder in an 81-year-old woman with pelvic lymph nodal and lung metastases.

Keywords: Clear cell carcinoma; Clear cell adenocarcinoma; Mesonephroma; Urinary bladder; Urology

Copyright link et al. This article is distributed under the terms of the Creative Commons Attribution License, which permits undertricted use and redistribution provided that the original author and source are credited.

Introduction

The transitional cell carcinoma (urothelial cell carcinoma) is the most common malignancy of the urinary bladder. Other major types include squamous cell carcinoma and adenocarcinoma. Primary clear cell carcinoma (CCC) is a rare entity in the bladder with less than 100 cases reported in current literature (see table 1).

42 case reports/series[1-42]	Alvarez et al. [3]
	A case report of CCC unsuccessfully treated with chemotherapy.
	Hartmann, Arndt et al. [4]
	A case revealing CCC can be a progression of nephrogenic metaplasia.
	Terada, Tadashi [5]
	An autopsy case where the cytoplasm of the CCC of the bladder was free from glycogen and mucins.
	Marchalik, Daniel et al. [6]
	A 26-year-old woman with Prune belly syndrome, cloacal anomaly and uterus didephys, who developed CCC of the bladder.
	Jassim, Sarmad H et al. [7]
	A case with concordant primary CCC of the bladder and primary lung adenocarcinoma with clear cell features.
	Diaz, Edward C et al. [8]
	An 8-year-old girl with primary CCC of the bladder. Good oncologic results with partial cystectomy.
	Lu, Ji et al. [9]
	A 68-year-old female with primary CCC of the bladder, who received intravesical therapy with mitomycin after TURB. Multiple tumor recurrences after therapy lead to the conclusion that intravesical therapy after TURB is not useful.
6 review articles [43-48]	Chan, Erica On-Ting et al. [47]
	The most recent systematic review, which shows 70 cases of clear cell carcinoma in current literature. Articles up till July 2020 were collected.
2 original articles [49-50]	Zhou et al. [49]
	CCC has a poorer prognosis compared to other bladder carcinomas due to higher tumor staging at diagnosis.
	Oliva, Esther et al. [50]
	The presence of CCC in the male population and its immunohistochemistry staining for CK7 and CK20, argues in favor of the hypothesis that CCC emanates from a peculiar form of gland differentiation in transitional (urothelial) cell carcinoma.

Table 1: Relevant articles retrieved on PubMed for CCC of the urinary bladder

Case report

An 81-year-old female with a history of endometriosis, hysterectomy and unilateral oophorectomy presented to the GP with abdominal complaints, gross hematuria, and general fatigue. A CT scan of the abdomen was performed which revealed a 5 x 6 x 4.5 cm tumor in the dorsal aspect of the bladder (Figure 1). As a result, the patient was referred to the gynecologist. Digital vaginal exam revealed a normal vaginal sac and transvaginal ultrasound confirmed a tumor solely in the dorsum of the urinary bladder. The patient was referred to the urology out-patient clinic. Cystoscopy showed that the tumor was located in the trigone and the bladder neck.



Panel A

Panel B

Figure 1: Abdominal sagittal (Panel A) and axial (Panel B) view of the CT scan shows an infiltrative mass located in the bladder dorsally. Margins are blurry and difficult to distinct.

The tumor mass was resected using transurethral resection (TUR); however, the TUR was incomplete due to the tumor size and its extension outside the bladder margins. Histopathology revealed a papillary proliferation of atypical cubic cells with large bulging hyperchromatic nuclei, as well

as tubule-cystic structures with hobnail type epithet-lium and solid sheets (Figure 2). The supplemental immunohistochemistry was positive for keratin 7, HNF-1Beta, Naspin and PAX 8, while negative for keratin 20, p63, ER, PR, WT-1, GATA-3, CDX2, TTF-1 and p40. P53 showed wild type expression.





Figure 2: Papillary (arrow 1), tubulo-cystic (arrow 2) and tubular (arrow 3) structures of hobnail epithelial cells with luminally protruding hyperchromatic nuclei and a modest degree of eosinophilic cytoplasm (arrow 4 & 5). (H&E, 100X).

An FDG-PET scan (Figure 3) was performed, which revealed lymphadenopathy of the right iliac region and perirectal fat. A small lung metastasis in the right lower lobe was also discovered. Imaging showed no involvement of the vaginal sac and there was no sign of invasion from outside the bladder. As stated above, the patient had undergone hysterectomy and unilateral ovariectomy in the past. Collectively, patient history, physical examination and histopathological results confirmed the diagnosis of primary clear-cell carcinoma of the bladder.

Palliative treatment options with chemo- and/or radiotherapy were discussed with the patient; given the metastasis, curative treatment was not an option. The patient initially opted for a wait-and-see policy, however four months after diagnosis decided for euthanasia route instead.



Panel 3

Figure 3: FDG-PET scan shows pelvic lymph nodal (Panel 1) and lung metastases (Panel 2). The tumor in the bladder is locally advanced as illustrated in panel 3.

Discussion

Primary clear cell carcinoma, also known as clear cell adenocarcinoma or mesonephroma, is a rare entity of cancer in the bladder. CCC was first described by Dow and Young in 1968 as mesonephric adenocarcinoma [14]. It is primarily a malignancy of the female genital tract. A recent thorough systematic review shows that there are currently only 70 cases of primary clear cell carcinoma in the urinary bladder described in the literature [47].

Patients usually present with hematuria or lower urinary tract symptoms, there are no other pathognomonic signs to be mentioned when CCC is involved [47]. CCC of the bladder is more common in younger age (< 60 years), black ethnicity and women [49].

The etiology of CCC in the bladder is unknown, however several hypotheses have been postulated [50,51] such as: CCC may emanate from Müllerian elements in the urinary bladder; the possibility of the involvement of the glandular tissue, such as endometriosis like genesis, in the bladder is also mentioned; CCC may represent a peculiar variant of vesical adenocarcinoma of non-Müllerian derivation and/or CCC represents a rare morphologic expression of transitional cell carcinoma, with glandular differentiation with uncertain pathway. Our patient's history of endometriosis and the immunohistochemical profile pointing at Mullerian origin strongly suggest and support the hypothesis that CCC of the urinary bladder emerges from endometriosis and thus emanates from Müllerian derivation.

Histologically, most CCC of the bladder consists of uniform ovoid cells with a clear cytoplasm [52]. The clear cytoplasm is due to the abundant amount of glycogen in the cell, which does not stain with H&E staining, therefore the cell appears clear under the microscope, hence the name: clear cell. Glycogen has shown to have an advancing role on tumor growth, particularly during demanding circumstances such as hypoxic and nutrient deprived conditions [49]. Furthermore, glycogen has also appeared to stimulate cellular proliferation and metastasis [53].

Glycogen abundance has been suggested to preserve the Warburg effect in tumor cells. The Warburg effect is a mechanism for faster growth using glucose even under hypoxic conditions and therefore enabling the cell for survival [54]. The capability of glycogen to enhance tumor survival in critical conditions may result in faster invasion of CCCs, which could explain the higher tumor staging at diagnosis [49].

CCC has a one-year survival rate of 69.1% [47] Currently, no standard treatment has been described in literature. The majority of patients with organ confined disease receive radical cystectomy which may be curative in some cases [47]. For muscle invasive tumors, Zhou et al. suggests total rather than partial cystectomy as it leads to better survival rates [49]. Several other case reports have shown that metastatic CCC is poorly responsive to chemotherapy or radiotherapy, though further research is needed to specify this [3, 48].

Conclusion

CCC is a rare type of malignancy seldom to be found in the urinary bladder, it has both progressive and aggressive biological behaviors. Currently, radical surgery is the primary treatment choice in organ confined disease. Radiotherapy and palliative chemotherapy have shown poor clinical responses. Further research is needed to find an effective, standard treatment to increase the survival rate of this malignant disease. Increased knowledge on the advancing role of glycogen on cancer metabolism, may also lead to new treatment pathways.

Funding

None

```
Conflicts of interest
```

None

```
Ethics approval
```

Not applicable

Consent to participate

Not applicable

Consent for publication

Personal details have been removed from this case description.

Availability of data and material

Not applicable

Code availability

Not applicable

Informed Consent

Informed consent is provided by the patient to publish anonymously.

Authors contribution

Z Hashemi wrote the manuscript.

H Roshani supervised and corrected the written manuscript.

KJ Lentjes reviewed and corrected the written manuscript.

D Houtsma reviewed and corrected the treatment options part of the manuscript.

R L Natté reviewed and corrected the pathological description of the specimen in the manuscript. RL Natté also contributed by sending illustrative and labeled images of the pathological specimen.

All authors read and approved the manuscript.

References

1. Abbas, Mahmoud, et al. (2013) "Adenocarcinoma of the urinary bladder, mesonephroid type: a rare case". Rare tumors 5.1: 11-14.

2. Adams, Betsy, et al. (2007) "A rare case of clear cell adenocarcinoma of the bladder with unique pathological features". The American journal of the medical sciences 333.1: 63-65.

3. Pena Alvarez, Carolina, et al. (2010) "Clear-cell adenocarcinoma of vesical origin: a case study of metastatic disease treated with chemotherapy". Chemotherapy research and practice.

4. Hartmann, Arndt, et al. (2006) "Molecular evidence for progression of nephrogenic metaplasia of the urinary bladder to clear cell adenocarcinoma". Human pathology 37.1: 117-120.

5. Terada, Tadashi (2013) "Urinary bladder urothelial carcinoma with expression of KIT and PDGFRA and showing diverse differentiations into plasmacytoid, clear cell, acantholytic, nested, and spindle variants, and into adenocarcinoma, signet-ring cell carcinoma, small cell carcinoma, large cell carcinoma, and pleomorphic carcinoma". International of clinical journal and experimental pathology 6.6: 1150.

6. Marchalik, Daniel, et al. (2015) "Clear cell adenocarcinoma of the bladder with intravesical cervical invasion". Case Reports bcr2015209893.

7. Jassim, Sarmad H, et al. (2017) "Concordant clear cell "mesonephric" carcinoma of the bladder and lung adenocarcinoma with clear cell features-multiple primaries versus metastatic neoplasms: a case report". Journal of medical case reports 11.1: 1-6.

8. Diaz Edward C et al. (2019) "2-year outcome for 8-year-old female managed with partial cystectomy for primary bladder clear cell carcinoma." <i>Urology case reports</i> 26: 100948.

9. Lu, Ji, et al. (2012) "Primary clear cell adenocarcinoma of the bladder with recurrence: a case report and literature review". World journal of surgical oncology 10.1: 33.

 Al-Izzi, MS, et al. (1989) "Malignant transformation in endometriosis of the urinary bladder". Histopathology 14.2: 191-8.

11. Butterworth DM, N Y Haboubi and EW Lupton. (1990) "Mixed mesonephric adenocarcinoma and transitional cell carcinoma of the bladder". Histopathology 16.6: 601-4.

12. Dow James A, and John D Young (1968) "Mesonephric adenocarcinoma of the bladder". The Journal of Urology 100.4: 466-9.

13. Kotliar, Sophia N, et al. (1995) "Transitional cell carcinoma exhibiting clear cell features. A differential diagnosis for clear cell adenocarcinoma of the urinary tract". Archives of pathology & laboratory medicine 119.1: 79-81.

14. Dhaliwal, Catharine A, and Paul W Fineron (2012) "The progression of nephrogenic metaplasia of the urinary bladder to clear cell adenocarcinoma: a case report". Current Urology 6.2: 106-8.

15. HONDA, Nobuaki, et al. (2000) "Mesonephric adenocarcinoma of the urinary bladder: a case report".

16. Isono, Makoto, et al. (2010) "Urothelial carcinoma clear cell variant of the urinary bladder: a case report". Hinyokika kiyo. Acta urologica Japonica 56.3: 163-5.

17. Miller, Eirwen M, et al. (2016) "Vesical clear cell adenocarcinoma arising from endometriosis: A mullerian tumor, indistinguishable from ovarian clear cell adenocarcinoma". Gynecologic Oncology Reports 18: 8-10.

 Minervini, R, U Urbano, and L Fiorentini (1984)
"Mesonephric adenocarcinoma of bladder". European urology 10: 141-2.

19. ITO, Kazuto, et al. (1999) "A case of adenocarcinoma with clear cell carcinoma of the bladder".

20. Odetola, Oluwatobi E, et al. (2018) "Unusual BK polyoma- virus associated urologic malignancies in renal transplant recipients: Report of two cases and review of the literature". Diagnostic Cytopathology 46.12: 1050-9.

21. Kurosaka, Shinji, et al. (2005) "Advanced clear-cell adenocarcinoma of the bladder successfully treated by radical surgery with adjuvant chemoradiotherapy". Inter- national Journal of Clinical Oncology 10.5: 362-5.

22. Kollsem, Mustafa, and Erdal Slengul (2005) "Clear cell adenocarcinoma of the urinary bladder". Scandinavian journal of urology and nephrology 39.1: 89-92.

23. Alsanjari, N, et al. (1995) "Vesical clear cell adenocarcinoma v. nephrogenic adenoma: a diagnostic problem". Histopathology 27.1: 43-9.

24. Kumar, Lalit, et al. (2019) "Primary clear-cell urothelial carcinoma of urinary bladder: a not-so-clear entity with review of literature". BMJ Case Reports CP 12.10: e231192.

25. Lah, Kevin, et al. (2013) "Primary vesical clear cell adenocarcinoma arising in endometriosis: a rare case of mullerian origin". Anticancer Research 33.2: 615-7.

26. Lum, Dennis (2006). "Clear cell carcinoma of the urinary bladder". Pathology 38.4: 367-70.

27. Mai KT (2000). "Multicentric clear cell adenocarcinoma in the urinary bladder and the urethral diverticulum: evidence of origin of clear cell adenocarcinoma of the female lower urinary tract from Mullerian duct remnants". Histopathology 36: 380-2.

28. Matsuoka, Yoh, et al. (2002). "Clear cell adenocarcinoma of the urinary bladder inducing acute renal failure". International journal of urology 9.8: 467-9.

29. Moradi, Mahmoudreza, et al. (2018). "Primary clear cell carcinoma of urinary bladder: A case report". Urology case reports 16: 41.

30. Loizzi V, et al. (2015). "A rare case of primary clear-cell adenocarcinoma of the bladder arising from bladder endometriosis". Journal of Obstetrics and Gynecology 35.7: 758-60.

31. Pers⊠ec, Zoran, et al. (2012). "Clear Cell Variant of Urothelial Carcinoma in Urinary Bladder; a Clinicopathological and Immunohistochemical Study–A Case Report". Collegium antropologicum 36.3: 1045-7.

32. Schultz, Roger E, et al. (1984). "Mesonephric

adenocarcinoma of the bladder". The Journal of urology 132.2: 263-5.

33. Kramer, Mario W, et al. (2012). "Clear-cell variant urothelial carcinoma of the bladder: a case report and review of the literature". Rare tumors 4.4: 153-5.

34. Signori, Gianbattista, et al. (2003). "Clear cell adenocarcinoma of the bladder in a male patient: clinicopathologic analysis of a case". Urologia internationalis 71.2: 228-30.

35. Skor, Arnold B, Michael M, Warren (1977). "Mesonephric adenocarcinoma of bladder". Urology 10.1: 64-5.

36. Yamashita, Ryo, et al. (2006). "Urothelial carcinoma (clear cell variant) diagnosed with useful immunohistochemistry stain". International journal of urology 13.11: 1448-50.

37. Minkowitz, Shaul Yosef, Reubina Wadee, Ahmed Adam (2016). "The first report of urothelial (clear cell variant) bladder cancer in a child". Urology 97: 204-7.

38. Moinzadeh, Alireza, Jerilyn Latini, Karim J, Hamawy (2003). "Clear cell adenocarcinoma of the urinary bladder within a diverticulum". Urology 62.1: 145.

39. Grosser, Daniel et al. (2021). "Clear Cell Adenocarcinoma in Men: A Series of 15 Cases." The American journal of surgical pathology vol. 45.2: 270-6.

40. Corongiu E, Grande P, Liberati E, Iacovelli R, Amini M et al. (2020). Clear Cell carcinoma of the urinary bladder, A case report: Surgical and oncological management. Arch Ital Urol Androl 2: 92.

41. Abdelwahab H, Friedman D, Lightle A, Mian B, Fisher H, et al. (2021). Distinct mutational status in GATA3-Positive clear cell adenocarcinoma of the urinary tract: A CASE report. Urol Case Rep

42. Zhang Y, Huang J, Feng H, Tang Y (2014). Primary multiple clear cell variant urothelial carcinomas of urinary bladder: a rare case report. Int J Clin Exp Pathol 7: 3385-8.

43. Drew, Peter A, et al. (1996). "The histogenesis of clear cell adenocarcinoma of the lower urinary tract: case series and review of the literature". Human pathology 27.3: 248-52.

44. Sun, Katherine, Youming Huan, Pamela D, Unger (2008). "Clear cell adenocarcinoma of urinary bladder and urethra: another urinary tract lesion immunoreactive for P504S". Archives of pathology & laboratory medicine 132.9: 1417-22.

45. Wang, Hanlin L, et al. (2001). "Immunohistochemical distinction between primary adenocarcinoma of the bladder and secondary colorectal adenocarcinoma". The Ameri- can journal of surgical pathology 25.11: 1380-7.

46. Young, Robert H, Robert E, Scully (1985). "Clear cell adenocarcinoma of the bladder and urethra: a report of three cases and review of the literature". The American journal of surgical pathology 9.11: 816-26.

47. Chan, Erica On-Ting et al. (2021). "Clear cell carcinoma of the urinary bladder: a systematic review." International urology and nephrology.

48. Sethi, Somika, Shashi Dhawan, Prem Chopra. (2011). "Clear cell adenocarcinoma of urinary bladder: A case report and review". Urology Annals 3.3: 151.

49. Zhou, Zhengqiu et al. (2020)."Clear Cell Adenocarcinoma of the Urinary Bladder Is a Glycogen-Rich 50. Oliva, Esther, et al. (2002). "Clear cell carcinoma of the urinary bladder: a report and comparison of four tumors of mullerian origin and nine of probable urothelial origin with discussion of histogenesis and diagnostic problems". The American journal of surgical pathology 26.2: 190-7.

51. Venyo, Anthony Kodzo-Grey (2014). "Primary Clear Cell Carcinoma of the Urinary Bladder." International scholarly research notices vol 593826: 2.

52. Gilcrease MZ et al. (1998). "Clear cell adenocarcinoma and nephrogenic adenoma of the urethra and urinary bladder: a histopathologic and immunohistochemical comparison." Human pathology vol. 29,12: 1451-6.

53. Schulze, Almut, Adrian L Harris (2012). "How cancer metabolism is tuned for proliferation and vulnerable to disruption." Nature vol. 491,7424: 364-73.

54. Shulman, Robert G, Douglas L Rothman (2017). "The Glycogen Shunt Maintains Glycolytic Homeostasis and the Warburg Effect in Cancer." Trends in cancer vol. 3,11: 761-7.

SMP Urol Res

SMP Family Medicine and Primary Care SMP Cardiology and Cardiovascular Medicine

